Both the FDA and the European CHMP have recommended and approved subcutaneous formulations of Keytruda, streamlining administration of this widely used cancer immunotherapy. This approval, alongside positive opinions for subcutaneous Lunsumio and insulin combo drugs, represents a shift towards more patient-friendly delivery routes in oncology and diabetes care. It promises improved convenience without compromising efficacy.